Cendakimab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Target | Interleukin 13 |
| Clinical data | |
| Other names | RPC4046; ABT 308; CC-93538 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
Cendakimab (RPC4046; ABT 308; CC-93538) is a monoclonal antibody against interleukin 13. It is developed by Bristol Myers Squibb[1] for eosinophilic esophagitis.[2][3][4]
References
[edit]- ^ "Pharmaceutical Research & Development Pipeline - Bristol Myers Squibb". www.bms.com. Retrieved 4 December 2023.
- ^ Syverson, Erin Phillips; Hait, Elizabeth (April 2022). "Update on Emerging Pharmacologic Therapies for Patients With Eosinophilic Esophagitis". Gastroenterology & Hepatology. 18 (4): 207–212. ISSN 1554-7914. PMC 9053490. PMID 35505944.
- ^ Caldwell, Julie; Ballaban, Adina; Li, Jie; Maddux, Rachel; Harris, Sarah; Rothenberg, Marc (February 2023). "Anti–IL-13 (cendakimab) administration improves esophageal gene expression in eosinophilic esophagitis". Journal of Allergy and Clinical Immunology. 151 (2): AB215. doi:10.1016/j.jaci.2022.12.670. S2CID 256589074.
- ^ Hirano, Ikuo; Collins, Margaret H.; Assouline-Dayan, Yehudith; Evans, Larry; Gupta, Sandeep; Schoepfer, Alain M.; Straumann, Alex; Safroneeva, Ekaterina; Grimm, Michael; Smith, Heather; Tompkins, Cindy-ann; Woo, Amy; Peach, Robert; Frohna, Paul; Gujrathi, Sheila; Penenberg, Darryl N.; Li, Caiyan; Opiteck, Gregory J.; Olson, Allan; Aranda, Richard; Rothenberg, Marc E.; Dellon, Evan S. (February 2019). "RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis". Gastroenterology. 156 (3): 592–603.e10. doi:10.1053/j.gastro.2018.10.051. PMID 30395812.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |